On Friday, BioXcel Therapeutics Inc (NASDAQ: BTAI) opened higher 4.58% from the last session, before settling in for the closing price of $1.31. Price fluctuations for BTAI have ranged from $1.17 to $18.08 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 6.20%. Company’s average yearly earnings per share was noted 75.36% at the time writing. With a float of $5.49 million, this company’s outstanding shares have now reached $6.06 million.
Let’s determine the extent of company efficiency that accounts for 37 employees. In terms of profitability, gross margin is -11.45%, operating margin of -2970.46%, and the pretax margin is -2163.17%.
BioXcel Therapeutics Inc (BTAI) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of BioXcel Therapeutics Inc is 9.26%, while institutional ownership is 6.33%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.
BioXcel Therapeutics Inc (BTAI) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 75.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 61.76% during the next five years compared to 6.20% growth over the previous five years of trading.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Check out the current performance indicators for BioXcel Therapeutics Inc (BTAI). In the past quarter, the stock posted a quick ratio of 1.45. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -13.52, a number that is poised to hit -1.86 in the next quarter and is forecasted to reach -3.89 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
Looking closely at BioXcel Therapeutics Inc (NASDAQ: BTAI), its last 5-days average volume was 22.19 million, which is a jump from its year-to-date volume of 2.87 million. As of the previous 9 days, the stock’s Stochastic %D was 5.73%.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 10.10%, which indicates a significant increase from 7.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.2030 in the past 14 days, which was higher than the 0.1970 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7088, while its 200-day Moving Average is $4.1223. However, in the short run, BioXcel Therapeutics Inc’s stock first resistance to watch stands at $1.8497. Second resistance stands at $2.3293. The third major resistance level sits at $2.5887. If the price goes on to break the first support level at $1.1107, it is likely to go to the next support level at $0.8513. Should the price break the second support level, the third support level stands at $0.3717.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
There are currently 6,056K shares outstanding in the company with a market cap of 8.30 million. Presently, the company’s annual sales total 2,270 K according to its annual income of -59,600 K. Last quarter, the company’s sales amounted to 170 K and its income totaled -7,250 K.
